| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/14787210.6.5.751 |
| P698 | PubMed publication ID | 18847410 |
| P50 | author | Eli Perencevich | Q56876774 |
| Sara E Cosgrove | Q96306300 | ||
| Lisa Lockerd Maragakis | Q113662133 | ||
| P2860 | cites work | Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients | Q24542412 |
| Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users | Q24675979 | ||
| Genome and virulence determinants of high virulence community-acquired MRSA | Q28202214 | ||
| Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms | Q28286917 | ||
| Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis | Q28333659 | ||
| Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms | Q28374448 | ||
| A new method of classifying prognostic comorbidity in longitudinal studies: development and validation | Q29547376 | ||
| APACHE II: a severity of disease classification system | Q29547729 | ||
| National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. | Q30977541 | ||
| A chronic disease score from automated pharmacy data | Q30983653 | ||
| Serotonin toxicity associated with the use of linezolid: a review of postmarketing data | Q31038983 | ||
| Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus | Q33378604 | ||
| Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome | Q33803393 | ||
| Health and economic impact of surgical site infections diagnosed after hospital discharge. | Q33984388 | ||
| Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome | Q34106854 | ||
| Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. | Q34301559 | ||
| Measuring the economic costs of antimicrobial resistance in hospital settings: summary of the Centers for Disease Control and Prevention-Emory Workshop | Q34385014 | ||
| The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges | Q34401421 | ||
| Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus | Q34454447 | ||
| Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. | Q34510547 | ||
| Vancomycin treatment of bacteremia caused by oxacillin-resistant Staphylococcus aureus: comparison with beta-lactam antibiotic treatment of bacteremia caused by oxacillin-sensitive Staphylococcus aureus. | Q54505796 | ||
| Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia | Q57212401 | ||
| Measuring the costs of nosocomial infections: Methods for estimating economic burden on the hospital | Q57274713 | ||
| The control of confounding by intermediate variables | Q34536408 | ||
| Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis | Q35030135 | ||
| Cost effect of managing methicillin-resistant Staphylococcus aureus in a long-term care facility | Q35048295 | ||
| The impact of antimicrobial resistance on health and economic outcomes | Q35136020 | ||
| Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility | Q35281765 | ||
| Reference group choice and antibiotic resistance outcomes | Q35880537 | ||
| The epidemiology and control of Acinetobacter baumannii in health care facilities | Q36382140 | ||
| Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes | Q36538655 | ||
| Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis | Q36937529 | ||
| Raising standards while watching the bottom line: making a business case for infection control | Q36969302 | ||
| Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization | Q37302581 | ||
| Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes | Q38461269 | ||
| Health and economic outcomes of vancomycin-resistant enterococci | Q38487139 | ||
| Predicting methicillin resistance and the effect of inadequate empiric therapy on survival in patients with Staphylococcus aureus bacteremia | Q39534248 | ||
| Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection | Q39721629 | ||
| Comorbidity risk-adjustment measures were developed and validated for studies of antibiotic-resistant infections. | Q40270951 | ||
| The distinction between cost and charges | Q40338665 | ||
| Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality | Q40382821 | ||
| Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children | Q40433501 | ||
| Comparison of methicillin-resistant and methicillin-sensitive Staphylococcus aureus bacteremia | Q40817810 | ||
| Effect of nosocomial infections due to antibiotic-resistant organisms on length of stay and mortality in the pediatric intensive care unit | Q43603202 | ||
| Excess shock and mortality in Staphylococcus aureus related to methicillin resistance. | Q43625221 | ||
| Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance | Q43712235 | ||
| Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center | Q43907192 | ||
| Clinical outcomes of meningitis caused by Streptococcus pneumoniae in the era of antibiotic resistance | Q44064229 | ||
| Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact | Q44132698 | ||
| Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection | Q44135229 | ||
| Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection | Q44320945 | ||
| Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes | Q44436393 | ||
| Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia | Q44453815 | ||
| An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome | Q44510164 | ||
| Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection | Q44686515 | ||
| A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection | Q44865966 | ||
| Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases | Q44943295 | ||
| Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children | Q45007740 | ||
| Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality | Q45101827 | ||
| Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species | Q45138017 | ||
| Utility of the Chronic Disease Score and Charlson Comorbidity Index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms | Q45271905 | ||
| Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia | Q46366731 | ||
| Mortality risk factors of Acinetobacter baumannii bacteraemia | Q46737697 | ||
| Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. | Q47646856 | ||
| Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. | Q50788076 | ||
| Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. | Q51194368 | ||
| A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. | Q54058047 | ||
| Enterococcus faecium bacteremia: does vancomycin resistance make a difference? | Q54144456 | ||
| P433 | issue | 5 | |
| P921 | main subject | antimicrobial resistance | Q63391344 |
| P304 | page(s) | 751-763 | |
| P577 | publication date | 2008-10-01 | |
| P1433 | published in | Expert Review of Anti-infective Therapy | Q15734432 |
| P1476 | title | Clinical and economic burden of antimicrobial resistance | |
| P478 | volume | 6 |
| Q47919706 | "Does this patient have…" "Is this patient at risk for infection with multidrug resistant bacteria?" |
| Q37057333 | A Survey and Analysis of the American Public's Perceptions and Knowledge About Antibiotic Resistance. |
| Q39094998 | A collaborative initiative for the containment of antimicrobial resistance in Mexico. |
| Q42066474 | A modified fluorescent intercalator displacement assay for RNA ligand discovery |
| Q35545776 | An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences. |
| Q34194422 | An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsis |
| Q91788081 | An overview of the antimicrobial resistance mechanisms of bacteria |
| Q64116653 | Analysis of Risk Factors for Multiantibiotic-Resistant Infections Among Surgical Patients at a Children's Hospital |
| Q91739695 | Anti-MRSA activity of a bioactive compound produced by a marine Streptomyces and its optimization using statistical experimental design |
| Q34366895 | Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens |
| Q28545750 | Antibiotic Restriction Might Facilitate the Emergence of Multi-drug Resistance |
| Q42571943 | Antibiotic resistance: who will pay the bills? |
| Q92713992 | Antibiotic utilisation in adult and children patients in Kosovo hospitals |
| Q58750126 | Antimicrobial Resistance Distribution Differs Among Methicillin Resistant Sequence Type (ST) 5 Isolates From Health Care and Agricultural Sources |
| Q38697988 | Antimicrobial Resistance in the Intensive Care Unit: A Focus on Gram-Negative Bacterial Infections |
| Q33564287 | Antimicrobial Stewardship Initiatives Throughout Europe: Proven Value for Money |
| Q38052855 | Antimicrobial resistance in internal medicine wards |
| Q84952839 | Antimicrobial stewardship as part of the infection prevention effort |
| Q26740379 | Antimicrobial stewardship in paediatrics |
| Q45232296 | Antimicrobial stewardship programs in pediatrics |
| Q26751621 | Association between infections caused by multidrug-resistant gram-negative bacteria and mortality in critically ill patients |
| Q33559105 | Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria |
| Q35682692 | Auranofin efficacy against MDR Streptococcus pneumoniae and Staphylococcus aureus infections. |
| Q37285118 | Bovine salmonellosis in northeast of Iran: frequency, genetic fingerprinting and antimicrobial resistance patterns of Salmonella spp. |
| Q39490187 | Burden of bloodstream infection caused by extended-spectrum β-lactamase-producing enterobacteriaceae determined using multistate modeling at a Swiss University Hospital and a nationwide predictive model |
| Q40766188 | Ceftaroline fosamil treatment outcomes compared with standard of care among hospitalized patients with complicated skin and soft tissue infections |
| Q39037981 | Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections. |
| Q51745780 | Characterization of the Lytic Capability of a LysK-Like Endolysin, Lys-phiSA012, Derived from a Polyvalent Staphylococcus aureus Bacteriophage. |
| Q34346016 | Clinical use of colistin induces cross-resistance to host antimicrobials in Acinetobacter baumannii |
| Q39855512 | Coping with antibiotic resistance: contributions from genomics. |
| Q92462357 | Costs of hospital-acquired Clostridium difficile infections: an analysis on the effect of time-dependent exposures using routine and surveillance data |
| Q34027016 | Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008 |
| Q92651289 | Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review |
| Q47735948 | Economic consequences of the demography of MRSA patients and the impact of broad-spectrum antimicrobials |
| Q36066041 | Economic value of dispensing home-based preoperative chlorhexidine bathing cloths to prevent surgical site infection |
| Q42115247 | Embracing ecology to limit antimicrobial resistance |
| Q39808330 | Engaging hospitalists in antimicrobial stewardship: Lessons from a multihospital collaborative. |
| Q36035185 | Evaluating state-specific antibiotic resistance measures derived from central line-associated bloodstream infections, national healthcare safety network, 2011. |
| Q42571408 | Evaluation of BBL CHROMagar VanRE for Detection of Vancomycin-Resistant Enterococci in Rectal Swab Specimens |
| Q40087078 | Evolving beta-lactamase epidemiology in Enterobacteriaceae from Italian nationwide surveillance, October 2013: KPC-carbapenemase spreading among outpatients |
| Q38705266 | Extended infusion of beta-lactam antibiotics: optimizing therapy in critically-ill patients in the era of antimicrobial resistance. |
| Q34077002 | Factors associated with variation in estimates of the cost of resistant infections |
| Q37785721 | Fighting Antibiotic Resistance: Marrying New Financial Incentives To Meeting Public Health Goals |
| Q38729839 | Functional metagenomic investigations of the human intestinal microbiota |
| Q48274901 | Immune-Stimulatory and Therapeutic Activity of Tinospora cordifolia: Double-Edged Sword against Salmonellosis |
| Q30388991 | Impact of an educational hands-on project on the antimicrobial, antitumor and anti-inflammatory properties of plants on Portuguese students' awareness, knowledge, and competences |
| Q91704558 | Impact of mechanical ventilation on the daily costs of ICU care: a systematic review and meta regression |
| Q92481810 | Implementation and impact of pediatric antimicrobial stewardship programs: a systematic scoping review |
| Q35166921 | Implementation of antimicrobial stewardship policies in U.S. hospitals: findings from a national survey |
| Q44374452 | Improving antimicrobial stewardship: the evolution of programmatic strategies and barriers |
| Q39336538 | In-vitro antimicrobial activity of marine actinobacteria against multidrug resistance Staphylococcus aureus |
| Q33767148 | Incidence and cost of hospitalizations associated with Staphylococcus aureus skin and soft tissue infections in the United States from 2001 through 2009 |
| Q37694529 | Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices |
| Q33719201 | Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B. |
| Q58577236 | Knowledge and Practice of Pharmacists toward Antimicrobial Stewardship in Pakistan |
| Q92890483 | Knowledge of antibiotic use and resistance among students of a medical school in Nigeria |
| Q30047328 | Long-term effect of computer-assisted decision support for antibiotic treatment in critically ill patients: a prospective ‘before/after’ cohort study |
| Q43630702 | Measuring the externality of antibacterial use from promoting antimicrobial resistance |
| Q58795935 | Mechanism of High-Level Daptomycin Resistance in |
| Q34456490 | Mechanisms of peptide-induced pore formation in lipid bilayers investigated by oriented 31P solid-state NMR spectroscopy |
| Q33774311 | Microbicidal effects of α- and θ-defensins against antibiotic-resistant Staphylococcus aureus and Pseudomonas aeruginosa |
| Q36078963 | Modeling non-inherited antibiotic resistance |
| Q44113426 | Mortality associated with in-hospital bacteraemia caused by Staphylococcus aureus: a multistate analysis with follow-up beyond hospital discharge |
| Q34686057 | Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study |
| Q64062755 | Multiple antibiotic resistance as a risk factor for mortality and prolonged hospital stay: A cohort study among neonatal intensive care patients with hospital-acquired infections caused by gram-negative bacteria in Vietnam |
| Q42559504 | One-day point prevalence of emerging bacterial pathogens in a nationwide sample of 62 German hospitals in 2012 and comparison with the results of the one-day point prevalence of 2010 |
| Q89879024 | Outcome Impacts Due to Pathogen-Specific Antimicrobial Resistance: A Narrative Review of Published Literature |
| Q34348698 | Overcoming drug resistance with alginate oligosaccharides able to potentiate the action of selected antibiotics. |
| Q58746821 | Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant |
| Q36937446 | Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa |
| Q36018548 | Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses |
| Q33506185 | Portuguese students' knowledge of antibiotics: a cross-sectional study of secondary school and university students in Braga. |
| Q40740383 | Postoperative Central Nervous System Infection After Neurosurgery in a Modernized, Resource-Limited Tertiary Neurosurgical Center in South Asia |
| Q60922609 | Prescription of Antibacterial Drugs for HIV-Exposed, Uninfected Infants, Malawi, 2004-2010 |
| Q41583518 | Prevention of colonization and infection by Klebsiella pneumoniae carbapenemase-producing enterobacteriaceae in long-term acute-care hospitals. |
| Q37745718 | Public knowledge, attitudes and practices regarding antibiotic use in Kosovo |
| Q35078345 | Public knowledge, attitudes, and experience regarding the use of antibiotics in Italy |
| Q39708430 | Resistance Elasticity of Antibiotic Demand in Intensive Care |
| Q43523403 | Resistance profiles of coagulase-negative staphylococci contaminating blood cultures predict pathogen resistance and patient mortality |
| Q82470159 | Risk factors for infections caused by multidrug-resistant bacteria in patients with solid tumours |
| Q33816251 | Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae |
| Q47154044 | Scientific Opinion on Carbapenem resistance in food animal ecosystems |
| Q92697098 | Self-medication of antibiotics: investigating practice among university students at the Malaysian National Defence University |
| Q58697600 | Surveillance of Antibiotic Prescribing in Intensive Care Units in Poland |
| Q50350775 | The Clinical Predictive Value (or Lack Thereof) of the Results of In Vitro Antimicrobial Susceptibility Tests |
| Q92571042 | The Clinical and Economic Impact of Antibiotic Resistance in China: A Systematic Review and Meta-Analysis |
| Q89357590 | The Current State of Antimicrobial Stewardship: Challenges, Successes, and Future Directions |
| Q33564316 | The Use of Bloodstream Infection Mortality to Measure the Impact of Antimicrobial Stewardship Interventions: Assessing the Evidence |
| Q30379659 | The antimicrobial activity of mecillinam, nitrofurantoin, temocillin and fosfomycin and comparative analysis of resistance patterns in a nationwide collection of ESBL-producing Escherichia coli in Norway 2010-2011. |
| Q37892237 | The challenges of antimicrobial drug resistance in Greece |
| Q30375493 | The changing epidemiology of hospital outbreaks due to ESBL-producing Klebsiella pneumoniae: the CTX-M-15 type consolidation. |
| Q60054146 | The drug use to treat community-acquired pneumonia in children: A cross-sectional study in China |
| Q46835800 | The effect of alginate oligosaccharides on the mechanical properties of Gram-negative biofilms. |
| Q59136153 | The importance of adjusting for enterococcus species when assessing the burden of vancomycin resistance: a cohort study including over 1000 cases of enterococcal bloodstream infections |
| Q37899213 | The role of the laboratory in choosing antibiotics |
| Q36066000 | Universal methicillin-resistant Staphylococcus aureus (MRSA) surveillance for adults at hospital admission: an economic model and analysis |
| Q92910885 | Use of antibiotics among end-of-life hospitalized patients with advanced directives: Status examination and association with infectious disease consultation and physician burnout |
| Q34990611 | Ventilator-associated tracheitis in children: does antibiotic duration matter? |
| Q94101148 | [Results of the implementation of an Antimicrobial Stewardship Program in the "Gerencia de Atención Integrada" of Alcazar de San Juan (Castilla La Mancha)] |
| Q34622345 | phiBIOTICS: catalogue of therapeutic enzybiotics, relevant research studies and practical applications. |
Search more.